Everest Medicines has acquired the rights from Corxel Pharmaceuticals to develop, manufacture, and commercialize VIZZ (LNZ100), an aceclidine-based eye drop for presbyopia, in Greater China. The drug's New Drug Application was submitted in China in September 2025, with approval expected by Q1 2027. LENZ Therapeutics, the original developer, will receive up to $85 million in milestones and royalties from sales in the region. This deal supports Everest's focus on ophthalmology and aims to provide a novel, non-invasive treatment option for the growing presbyopia patient population in China and surrounding areas.
Morpho Midnight is a new DeFi lending protocol offering fixed-rate loans with set maturity dates, replacing traditional floating-rate models. It pools liquidity across markets sharing the same end date to prevent fragmentation and allows lenders to k...
Bitcoin rose above $61,800, with Ethereum outperforming by gaining over 4%, signaling a modest risk-on shift in the crypto market. Several major altcoins also saw gains, indicating improving sentiment beyond Bitcoin. However, trading volumes across s...
Odysight.ai has established an At-The-Market (ATM) program allowing it to sell up to $20 million of its common stock to enhance financial flexibility. This program, managed with Roth Capital Partners, provides the company with a flexible way to raise...
A New York Supreme Court judge has paused a lawsuit seeking ownership of 39,069 dormant Bitcoin wallets holding an estimated 3.8 million BTC valued at around $234 billion. The plaintiffs rely on New York's lost-and-found statute, but an amicus brief ...
Toncoin (TON) surged 13.36% to $1.70, recovering from recent lows despite a 16.51% drop in spot volume, indicating limited broad market support. Futures data showed continued selling pressure, suggesting the rally was driven by passive buying or shor...
